Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

The 1982 revised criteria for the classification of systemic lupus erythematosus

Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations

Life Sciences, Immunology, Internal Medicine +14

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus

Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón et al. · Arthritis & Rheumatism · 2012 · 5.3K citations · Full text

Life Sciences, Immunology, Clinical Classification Systems +11

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor, Edward Keystone, Désirée van der Heijde et al. · New England Journal of Medicine · 2017 · 951 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus

Richard Furie, Munther A. Khamashta, Joan T. Merrill et al. · Arthritis & Rheumatology · 2016 · 867 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Mark C. Genovese, Joel Kremer, Omid Zamani et al. · New England Journal of Medicine · 2016 · 621 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16